Evidence for the Use of Secukinumab in Patients with Radiographic and Non-radiographic Axial Spondyloarthritis in the Last 5 Years

Aparicio, M.; Astete, Carlos Antonio Guillén; López-Medina, Clementina; Sastré, C.; Martínez, F.

doi:10.1007/s40744-021-00400-1

Cited by 6 publications

(4 citation statements)

References 83 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The findings on sex were consistent with the MEASURE studies, where drug survival was comparable between male and female axSpA patients treated with secukinumab over 52 weeks ( 43 ). Similarly, in pooled analyses of the MEASURE studies, secukinumab was effective in patients with r-axSpA regardless of their HLA-B27 status ( 19 , 25 , 43 , 49 ). Other than the aforementioned factors, baseline patient characteristics did not have a major impact on the overall secukinumab retention in this study, except for disease duration and concomitant peripheral involvement.…”

Section: Discussionmentioning

confidence: 88%

Four-year real-world experience of secukinumab in a large Italian cohort of axial spondyloarthritis

Ramonda,

Lorenzin,

Chimenti

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

ObjectivesThis study aims to evaluate in a real-life Italian multicenter cohort of axial spondyloarthritis (axSpA) (1) the 4-year effectiveness and safety of secukinumab, (2) the drug retention rate (DRR), and (3) the impact of the line of bDMARDs treatment, subtype of axSpA, and sex on achieving low disease activity (LDA) and very low disease activity (VLDA).MethodsConsecutive axSpA patients receiving secukinumab between 2016 and 2023 were prospectively evaluated. Data on disease characteristics, previous/ongoing treatments, comorbidities, and follow-up duration were collected. Treatment response was evaluated at 6 and 12 months after initiation and yearly up to 48 months (T48). DRR and effectiveness outcomes were evaluated according to bDMARDs treatment, axSpA subtype, and sex. Infections and adverse events (AEs) were recorded.ResultsWe enrolled 272 patients (48.2% male; median age, 51; 39.7% HLA-B27+; 40.4% nr-axSpA), of whom 30.9% were naïve to secukinumab. Overall, secukinumab yielded improvement in effectiveness outcomes; the naïve patients maintained lower disease activity vs. the non-naïve ones. At T48, the LDA and VLDA rates were higher in naïve patients and in male individuals. Treatment was discontinued in 104 patients due to primary/secondary loss of effectiveness and in 34 patients due to AEs. The DRR at T48 was 67.4% in the whole population, regardless of treatment line, axSpA subtype, and sex.ConclusionsSecukinumab was safe and effective in all axSpA patients irrespective of treatment line, disease subtype, and sex. The patients achieved sustained 4-year remission and DRR.

show abstract

Section: Discussionmentioning

confidence: 88%

Four-year real-world experience of secukinumab in a large Italian cohort of axial spondyloarthritis

Ramonda,

Lorenzin,

Chimenti

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…Examples of other drugs in this class include ustekinumab (Stelara ® , Janssen Pharmaceuticals of Johnson and Johnson), bimekizumab [Bimzelx ® , UCB (Union Chimique Belge)], secukinumab (Cosentyx ® , Novartis) and ixekizumab (Taltz, Lilly). This class of drugs has shown effectiveness in treating a range of autoimmune diseases such as plaque psoriasis, psoriatic arthritis, axial spondylarthritis and ankylosing spondylitis (Glatt et al, 2017;Gordon et al, 2021;Loricera et al, 2021;Aparicio et al, 2022;Kolbinger et al, 2022;Oliver et al, 2022) representing an important new treatment tool. Like GP2017 however, these biotherapeutics must be delivered by injection.…”

Section: Discussionmentioning

confidence: 99%

Transenteric delivery of antibodies via an orally ingestible robotic pill yields high bioavailability comparable to parenteral administration in awake canines

Yamaguchi

Dam²,

Dhalla³

et al. 2022

Front. Drug. Deliv.

View full text Add to dashboard Cite

Biotherapeutics such as peptides and antibodies are highly efficacious clinically but, unlike conventional medications, cannot be administered orally as they get digested and inactivated. Thus, biotherapeutics require parenteral routes for delivery, such as intravenous, intramuscular or subcutaneous administration. However, these delivery methods have limitations such as poor patient compliance or may require clinical supervision compared to oral therapies. We explored whether a novel, orally administered transenteric delivery system (Robotic Pill) could provide equivalent bioavailability to parenterally administered drugs. Utilizing an awake canine model, we demonstrated that orally administered Robotic Pills containing either human IgG or an anti-cytokine monoclonal antibody directed against either TNFα or interleukin-17A yielded bioavailability equivalent to parenterally administered controls. The ability to achieve clinically relevant blood levels of biotherapeutics via any orally administered preparation represents an important advance in drug delivery.

show abstract

“…Because of the inhibition of the effects of IL-17A, which is a pro-inflammatory cytokine, there is the standardization of immune function and histology of skin as it interferes with psoriasis disease pathways. 16 Secukinumab neutralizes IL-17A without neutralizing interleukin-17F at curative doses used for psoriasis. In comparison to other therapies, this target gives fewer side effects.…”

Section: Secukinumab In Psoriasismentioning

confidence: 99%

Secukinumab: A Silver Lining in Dermatology

Dhanaraj

Srinivasan

et al. 2022

Journal of Pharmacology and Pharmacotherapeutics

View full text Add to dashboard Cite

Secukinumab, a fully human monoclonal antibody, is a biological agent that targets interleukin-17A. Secukinumab is used in the management of the common dermatological entity - plaque-type psoriasis and its various types, namely psoriatic arthritis, hypertrophic palmoplantar psoriasis and generalized pustular psoriasis. Other less common indications of this popular interleukin -17A inhibitor, secukinumab include ankylosing spondylitis, rheumatoid arthritis, systemic lupus erythematosus, Familial Mediterranean fever, and tumor necrosis factor receptor-associated periodic syndrome (TRAPS). This review article was written by referring to various review articles, original articles, and some books related to highly regarded databases, such as the Web of Science, PubMed, and Scopus. The keywords explored during review of literature consisted of combinations of the following words: human monoclonal antibody, IL-17A, and biologicals. The authors with this in-depth review hope to explore the working of this versatile biological, Secukinumab, especially as a silver lining in dermatology.

show abstract

Evidence for the Use of Secukinumab in Patients with Radiographic and Non-radiographic Axial Spondyloarthritis in the Last 5 Years

Cited by 6 publications

References 83 publications

Four-year real-world experience of secukinumab in a large Italian cohort of axial spondyloarthritis

Four-year real-world experience of secukinumab in a large Italian cohort of axial spondyloarthritis

Transenteric delivery of antibodies via an orally ingestible robotic pill yields high bioavailability comparable to parenteral administration in awake canines

Secukinumab: A Silver Lining in Dermatology

Contact Info

Product

Resources

About